Currently, there are 44.68M common shares owned by the public and among those 41.07M shares have been available to trade.
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 22,950 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 3.0700, up 64.87%. The company’s stock has a 5-day price change of 74.25% and 140.50% over the past three months. CRDF shares are trading 96.62% year to date (YTD), with the 12-month market performance up to 69.19% higher. It has a 12-month low price of $0.94 and touched a high of $2.79 over the same period. CRDF has an average intraday trading volume of 190.08K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 68.67%, 79.92%, and 91.85% respectively.
Institutional ownership of Cardiff Oncology Inc (NASDAQ: CRDF) shares accounts for 12.13% of the company’s 44.68M shares outstanding.
It has a market capitalization of $130.02M and a beta (3y monthly) value of 1.71. The earnings-per-share (ttm) stands at -$0.93. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.00% over the week and 10.32% over the month.
Analysts forecast that Cardiff Oncology Inc (CRDF) will achieve an EPS of -$0.28 for the current quarter, -$0.3 for the next quarter and -$1.78 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.31 while analysts give the company a high EPS estimate of -$0.25. Comparatively, EPS for the current quarter was -$0.25 a year ago. Earnings per share for the fiscal year are expected to decrease by -4.22%, and -8.84% over the next financial year.
Robert W. Baird coverage for the Cardiff Oncology Inc (CRDF) stock in a research note released on December 08, 2021 offered a Outperform rating with a price target of $19. Maxim Group was of a view on August 09, 2021 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on October 22, 2020, issuing a price target of $27. Piper Sandler on their part issued Overweight rating on October 08, 2020.
